Ependymoma - Pipeline Review, H2 2019

November 2019 | 237 pages | ID: EFF6FF56921EN
Global Markets Direct

Abstracts

Ependymoma - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma - Pipeline Review, H2 2019, provides an overview of the Ependymoma (Oncology) pipeline landscape.

Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of the cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow growing tumours, and any signs and symptoms usually develop slowly over many months. The treatment for an ependymoma depends on a number of things, including general health, the size and position of the tumour, and whether it has spread to other parts of the brain or spinal cord.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ependymoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ependymoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ependymoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase I stages are 11 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ependymoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Ependymoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Ependymoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Ependymoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Ependymoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Ependymoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Ependymoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Ependymoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Ependymoma - Overview
Ependymoma - Therapeutics Development
Ependymoma - Therapeutics Assessment
Ependymoma - Companies Involved in Therapeutics Development
Ependymoma - Drug Profiles
Ependymoma - Dormant Projects
Ependymoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Ependymoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Ependymoma - Pipeline by AstraZeneca Plc, H2 2019
Ependymoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2019
Ependymoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Ependymoma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Ependymoma - Pipeline by Celgene Corp, H2 2019
Ependymoma - Pipeline by Eli Lilly and Co, H2 2019
Ependymoma - Pipeline by Kite Pharma Inc, H2 2019
Ependymoma - Pipeline by Mana Therapeutics Inc, H2 2019
Ependymoma - Pipeline by NewLink Genetics Corp, H2 2019
Ependymoma - Pipeline by Novartis AG, H2 2019
Ependymoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Ependymoma - Pipeline by Pfizer Inc, H2 2019
Ependymoma - Pipeline by Y-mAbs Therapeutics Inc, H2 2019
Ependymoma - Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ependymoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

AstraZeneca Plc
Bexion Pharmaceuticals LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celgene Corp
Eli Lilly and Co
Kite Pharma Inc
Mana Therapeutics Inc
NewLink Genetics Corp
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
Y-mAbs Therapeutics Inc